

Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients

[Tetsuya Nakatsura](#)^{*}, Kazumasa Takenouchi, Jun Kataoka, Yusuke Ito, Sae Kikuchi, Hiroki Kinoshita, [Kazunobu Ohnuki](#), [Toshihiro Suzuki](#), [Nobuo Tsukamoto](#)

Posted Date: 29 January 2025

doi: 10.20944/preprints202501.2158.v1

Keywords: common cancer antigens; CAR-T cell therapy; membrane protein; solid cancer; glypican-3; ROBO; EphB4; CLDN1; LAT; cocktail CAR-T



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients

Tetsuya Nakatsura *, Kazumasa Takenouchi, Jun Kataoka, Yusuke Ito, Sae Kikuchi, Hiroki Kinoshita, Kazunobu Ohnuki, Toshihiro Suzuki and Nobuo Tsukamoto

Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer center, Kashiwa 277-8577, Japan; katakeno@east.ncc.go.jp (K.T.); jkataoka@east.ncc.go.jp (J.K.); yusito@east.ncc.go.jp (Y.I.); sakikuc4@east.ncc.go.jp (S.K.); hirokino@east.ncc.go.jp (H.K.); konuki@east.ncc.go.jp (K.O.); toshsuzu@east.ncc.go.jp (T.S.); nobutsuk@east.ncc.go.jp (N.T.)

* Correspondence: tnakatsu@east.ncc.go.jp; Tel.: ++81-4-7131-5490

Abstract: Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to “overcome the heterogeneity of cancer antigens.” For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In addition, it was revealed that the cell membrane antigens EphB4, CLDN1, and LAT1 are frequently expressed in various solid cancers. CAR-T cell therapy targeting these antigens may be a savior for many solid cancer patients. We will develop cancer immunotherapies that target these multiple common cancer membrane protein antigens.

Keywords: common cancer antigens; CAR-T cell therapy; membrane protein; solid cancer; glypican-3; ROBO; EphB4; CLDN1; LAT; cocktail CAR-T

1. Introduction

The success of immune checkpoint inhibitor therapy, CD19 chimeric antigen receptor (CAR)-T cell therapy, and COVID-19 mRNA vaccines shows that eradicating cancer is not a dream if we can mobilize diverse and healthy T cells to cancer through developing effective cancer vaccines and T cell therapy. On the other hand, the development of cancer vaccines has failed completely, and no cancer vaccine has been approved yet. CAR-T cell therapy, which is effective against blood cancer, is not effective against solid cancers. There are several possible reasons why cancer vaccines and CAR-T are ineffective against solid cancers. Still, we are going back to the basics and asking ourselves whether the cancer cells are expressing the cancer antigens we are targeting in the first place. We discovered the cancer-specific antigen glypican-3 (GPC3) and identified peptides that can induce cytotoxic T lymphocytes (CTLs) in an HLA-A24 or -A2-restricted manner and conducted clinical trials of peptide vaccines for hepatocellular carcinoma, ovarian clear cell carcinoma, and pediatric cancer [1–18]. We have experienced successful cases even in advanced cancers, demonstrating the possibility of preventing recurrence. Seven children with childhood cancer who received this vaccine are still

growing healthy and without recurrence for about 10 years. We are currently identifying T cell receptors (TCRs) from the peptide-specific CTL clones of this girl who overcame hepatoblastoma and developing TCR-T cell therapy. GPC3 is expressed in normal organs such as the placenta, fetal liver, kidneys, and lungs but rarely in normal organs in adults. It is an extremely safe cancer antigen, but unfortunately, it is only expressed in a limited number of cancer types. GPC3 is also a membrane protein, and CAR-T cell therapy targeting GPC3 has been developed worldwide, but dramatic efficacy has not yet been reported. Our immunohistochemical analysis has shown that GPC3 is expressed in many hepatocellular carcinomas, but the expression pattern on the cell membrane is rare. To increase the effectiveness of CAR-T cell therapy, the antigen must be properly expressed on the cell membrane of most cancer cells. Cancer has heterogeneity, and it is not possible to eradicate cancer by targeting only one antigen. In fact, in clinical trials of GPC3 peptide vaccines, the vaccine was administered to prevent recurrence after hepatocellular carcinoma resection, but we experienced several cases of GPC3-negative cancer recurrence. Therefore, in this study, we challenged ourselves to collect some common cancer membrane protein antigens, including GPC3, expressed in a wide range of solid cancers but only in limited amounts in normal tissues. To be a promising target for CAR-T cell therapy, the antigen must be expressed on the cell membrane of cancer cells. In this study, we added roundabout guidance receptor 1 (ROBO1) [21–23], Eph receptor B4 (EphB4) [24–29], claudin-1 (CLDN1) [30–33], and L-type amino acid transporter 1 (LAT1) [34–37] to GPC3, which we have studied so far. We verified the expression of these five common cancer antigens on the cell membrane of cancer cells by immunohistochemical analysis of tissue sections, including cancerous and non-cancerous areas of various solid cancers, to find combinations of these common cancer membrane protein antigens that are promising targets for CAR-T cell therapy targeting all solid cancers.

2. Results

2.1. Representative Examples of Plasma Membrane Expression of Five Common Cancer Antigens in Cancer Cells

Representative examples of five common cancer antigens, GPC3, ROBO1, CLDN1, EphB4, and LAT1, expressed on the cell membrane of cancer cells are shown (Figure 1). CLDN1, EphB4, and LAT1 were expressed only on the cell membrane of cancer cells. In contrast, GPC3 and ROBO1 were mainly expressed in the cytoplasm of cancer cells, although some expression patterns on the cell membrane of cancer cells were observed.




Figure 1. Representative examples of plasma membrane expression of five common cancer antigens in cancer cells. Representative examples of five common cancer antigens, GPC3, ROBO1, CLDN1, EphB4, and LAT1, expressed on the cell membrane of cancer cells are shown.

2.2. Expression Frequency of Five Common Cancer-Specific Antigens in Various Solid Cancers and Their Expression Frequency as Cell Membrane Proteins

Immunostaining was performed using formalin-fixed paraffin sections, including cancerous and non-cancerous areas, from a total of 385 cases of advanced cancer that had been surgically resected.

The breakdown of the 385 cases is as follows: 57 cases of head and neck cancer (21 oral cancer, 36 pharyngeal cancer), 36 breast cancer, 16 esophageal squamous cell carcinoma, 72 lung cancer (45 adenocarcinoma, 27 squamous cell carcinoma), 29 gastric cancer (including 19 endoscopically resected early stage 1 gastric cancer), 20 hepatocellular carcinoma, 30 biliary tract cancer (10 intrahepatic bile duct cancer, 10 extrahepatic bile duct cancer, 10 gallbladder cancer), 13 pancreatic cancer, 15 colorectal cancer, 19 renal cell carcinoma, 18 ovarian cancer (17 serous adenocarcinoma, 1 clear cell carcinoma), 7 uterine cancer, 20 melanoma (7 ALM, 5 mucosal mucous, 5 SSM, 3 LMM), 33 childhood cancer (9 hepatoblastoma, 8 neuroblastoma: Wilms tumor, 10 nephroblastoma, 6 germ cell tumor) (Figure 2, Table 1).




Figure 2. Expression frequency of 5 common cancer-specific antigens in various solid cancers and their expression frequency as cell membrane proteins. Representative examples of the expression patterns of 5 common cancer-specific antigens in each cancer type by their intracellular localization (cell membrane, cytoplasm) in cancer tissues are shown.

In this study, we investigated the expression of ROBO1, a protein known to be expressed on the cell membrane of hepatocellular carcinoma, in various types of cancer. It was revealed that ROBO1 is mainly expressed in cytoplasm, and when cases with cell membrane expression patterns were also included, it was surprisingly frequently expressed in all cancers. The positive rates were high at 90-100% in all cancers except renal cell carcinoma (63%) and breast cancer (71%), and the positive rate was 93% in all cancers (data not shown).

Table 1					
Expression of five kinds of common cancer antigens on the cell membrane in various solid cancers					
Common cancer antigens*	CLDN1	EphB4	LAT1	ROBO1	GPC3
Head and neck cancer	44/44 (100)	53/56 (95)	41/44 (93)	13/44 (30)	3/57 (5)
oral cancer	14/14 (100)	20/20 (100)	14/14 (100)	2/14 (14)	0/21 (0)
pharyngeal cancer	30/30 (100)	33/36 (92)	27/30 (90)	11/30 (37)	3/36 (8)
Breast cancer	7/36 (20)	30/36 (83)	15/36 (42)	2/35 (6)	0/36 (0)
Esophageal cancer	15/16 (94)	15/16 (94)	15/16 (94)	6/16 (38)	1/16 (6)
Lung cancer	45/72 (63)	57/72 (79)	49/72 (68)	19/72 (26)	4/72 (6)
adenocarcinoma	20/45 (44)	35/45 (78)	22/45 (49)	5/45 (11)	1/45 (2)
squamous cell carcinoma	25/27 (93)	22/27 (81)	27/27 (100)	14/27 (52)	3/27 (11)
Gastric cancer	14/29 (48)	27/29 (93)	12/29 (41)	0/29 (0)	0/19 (0)
advanced	8/10 (80)	10/10 (100)	8/10 (80)	0/10 (0)	NT
early	6/19 (32)	17/19 (89)	4/19 (21)	0/19 (0)	0/19 (0)
Biliary cancer	26/28 (93)	24/30 (80)	10/20 (50)	6/29 (21)	0/20 (0)
intrahepatic	7/ 8 (88)	10/10 (100)	NT	2/10 (20)	NT
extrahepatic	10/10 (100)	7/10 (70)	4/10 (40)	3/10 (30)	0/10 (0)
gallbladder	9/10 (90)	7/10 (70)	6/10 (60)	1/ 9 (11)	0/10 (0)
Pancreatic cancer	11/11 (100)	9/12 (75)	4/13 (31)	0/11 (0)	0/12 (0)
Hepatocellular carcinoma	13/20 (65)	14/20 (70)	0/14 (0)	14/19 (74)	1/20 (5)
Colorectal cancer	15/15 (100)	14/15 (93)	15/15 (100)	0/15 (0)	0/15 (0)
Renal cell carcinoma	3/19 (16)	0/19 (0)	3/19 (16)	2/19 (11)	0/19 (0)
Ovarian cancer	17/18 (94)	15/18 (83)	12/18 (67)	0/18 (0)	1/18 (6)
serous adenocarcinoma	16/17 (94)	14/17 (82)	11/17 (65)	0/17 (0)	0/17 (0)
clear cell carcinoma	1/ 1 (100)	1/ 1 (100)	1/ 1 (100)	0/ 1 (0)	1/ 1 (100)
Uterine cancer	7/ 7 (100)	6/ 7 (86)	7/ 7 (100)	1/ 7 (14)	0/ 7 (0)
Pediatric cancer	15/33 (45)	13/33 (39)	14/33 (42)	16/32 (50)	9/33 (27)
hepatoblastoma	9/ 9 (100)	8/ 9 (89)	2/ 9 (22)	6/ 9 (67)	3/ 9 (33)
nephroblastoma	4/10 (40)	3/10 (30)	3/10 (30)	8/10 (80)	5/10 (50)
germ cell tumors	2/ 6 (33)	2/ 6 (33)	6/ 6 (100)	1/ 6 (17)	1/ 6 (17)
neuroblastoma	0/ 8 (0)	0/ 8 (0)	3/ 8 (38)	1/ 7 (14)	0/ 8 (0)
Melanoma	5/20 (25)	13/20 (65)	11/20 (55)	2/20 (10)	0/20 (0)
ALM	0/ 7 (0)	4/ 7 (57)	3/ 7 (43)	0/ 7 (0)	0/ 7 (0)
MM	0/ 5 (0)	5/ 5 (100)	4/ 5 (80)	2/ 5 (40)	0/ 5 (0)
SSM	3/ 5 (60)	3/ 5 (60)	3/ 5 (60)	0/ 5 (0)	0/ 5 (0)
LMM	2/ 3 (67)	1/ 3 (33)	1/ 3 (33)	0/ 3 (0)	0/ 3 (0)
Total	237/368 (64)	290/383 (76)	208/356 (58)	81/366 (22)	19/364 (5)

* CLDN1: Claudin 1, EphB4: Ephrin type-B receptor 4, LAT1: L-type amino acid transporter 1, ROBO1: Roundabout Homolog-1, GPC3: glypican-3

GPC3 is well-known as a membrane protein. Still, our previous research has revealed that it is also a secretory protein, is often expressed in cytoplasm, and is expressed in a limited number of cancer types. Consistent with known results, GPC3 is expressed in 60% of hepatocellular carcinoma, 100% of hepatoblastoma, 90% of nephroblastoma: Wilms tumor, 50% of germ cell tumor, 37% of lung squamous cell carcinoma, and ovarian clear cell carcinoma. It was also positive in 25% of pharyngeal cancer, 13% of esophageal cancer, 11% of early gastric cancer, 30% of gallbladder cancer, 24% of ovarian serous adenocarcinoma, and one case each of oral cancer, lung adenocarcinoma, colon cancer, uterine cancer, neuroblastoma, and melanoma. The overall positive rate was only 19% (data not

shown). A feature of this study is that we conducted a large-scale investigation of the expression of these five membrane protein antigens on the cell membrane (Table 1). The positive rate of GPC3 expression on the cell membrane was only 5% in hepatocellular carcinoma, 33% in hepatoblastoma, 50% in nephroblastoma: Wilms tumor, 17% in germ cell tumor, 11% in lung squamous cell carcinoma, one case of ovarian clear cell carcinoma, 8% in pharyngeal cancer, and 6% in esophageal cancer, as well as one case each of ovarian serous adenocarcinoma and lung adenocarcinoma. Overall, this sharply declined to 5% compared to the positive rate of 19%, including the aforementioned cytoplasmic expression. ROBO1 was also expressed on the cell membrane in 37% of pharyngeal cancer, 14% of oral cancer, 6% of breast cancer, 38% of esophageal cancer, 52% of lung squamous cell carcinoma, 11% of lung adenocarcinoma, 21% of biliary tract cancer, 74% of hepatocellular carcinoma, 11% of renal cell carcinoma, 14% of uterine cancer, 67% of hepatoblastoma, 80% of nephroblastoma, 17% of germ cell tumor, 14% of neuroblastoma, and 10% of melanoma. The overall positive rate of expression on the cell membrane dropped sharply from 93%, which is the positive rate, including the expression in the cytoplasm mentioned above, to 22%. However, it was revealed that ROBO1 is frequently expressed on the cell membrane in hepatocellular carcinoma, pediatric cancer, lung squamous cell carcinoma, pharyngeal cancer, and esophageal cancer, suggesting that CAR-T cell therapy targeting ROBO1 may be effective against these cancer types.

The greatest achievement of this study was demonstrating that three kinds of cell membrane-expressing proteins, CLDN1, EphB4, and LAT1, are frequently expressed in various types of solid cancers (Figure 2, Table 1). CLDN1 was positive in 100% of oral and pharyngeal cancer, 94% of esophageal cancer, 93% of lung squamous cell carcinoma, 80% of gastric cancer, 93% of biliary tract cancer, 100% of pancreatic cancer, 100% of colorectal cancer, 94% of ovarian cancer, 100% of uterine cancer, and 100% of hepatoblastoma, as well as 65% of hepatocellular carcinoma, 44% of lung adenocarcinoma, 40% of nephroblastoma: Wilms tumor, and 33% of germ cell tumor. An interesting finding was that the positive rate of 32% for early gastric cancer was low compared to 80% for advanced gastric cancer. On the other hand, the positive rate was 25% for melanoma, 16% for renal cell carcinoma, only 2% for breast cancer, and 0% for neuroblastoma, resulting in an overall positive rate of 64%. Next, EphB4 showed high positive rates in 100% of oral cancer, 92% of pharyngeal cancer, 83% of breast cancer, 94% of esophageal cancer, 79% of lung cancer, 100% of gastric cancer (including 89% of early gastric cancer), 80% of biliary tract cancer, 75% of pancreatic cancer, 70% of hepatocellular carcinoma, 93% of colorectal cancer, 83% of ovarian cancer, 86% of uterine cancer, 89% of hepatoblastoma, and 65% of melanoma. The positive rates were 30% in nephroblastoma: Wilms tumor, 33% in germ cell tumor, and 0% in renal cell carcinoma and neuroblastoma: Wilms tumor, resulting in an overall positive rate of 76%. Finally, the positive rates of LAT1 were 100% for oral cancer, 90% for pharyngeal cancer, 94% for esophageal cancer, 100% for lung squamous cell carcinoma, 80% for gastric cancer, 100% for colorectal cancer, 67% for ovarian cancer, 100% for uterine cancer, 100% for germ cell tumor, 55% for melanoma, 50% for biliary tract cancer, 49% for lung adenocarcinoma, 42% for breast cancer, 38% for neuroblastoma, 31% for pancreatic cancer, and 30% for nephroblastoma. An interesting finding was that the positive rate for LAT1 was 21% for early gastric cancer compared to 80% for advanced gastric cancer. The other positive rates were 22% for hepatoblastoma, 16% for renal cell carcinoma, and 0% for hepatocellular carcinoma, resulting in an overall positive rate of 58%.

2.3. Expression of Five Common Cancer Membrane Protein Antigens in Non-Cancerous Normal Organs Adjacent to Various Cancers

Figure 3 shows representative examples of the expression patterns of five common cancer membrane protein antigens in non-cancerous normal organs (pharynx, mammary gland, esophagus, lung, stomach, liver, gallbladder, pancreas, colon, kidney, ovary, uterus, and skin) adjacent to the cancer lesions of a total of 385 cases of surgically resected advanced cancer as described above. Our previous study showed that GPC3 is expressed in the placenta and fetal liver, kidney, and lung but is rarely expressed in normal adult organs, except for weak expression in renal tubular cells. Similar

results were obtained this time as well. ROBO1 staining was observed in the basal layer cells of the squamous epithelium of the pharynx and esophagus and in the mucosal epithelium cells of the stomach and gallbladder, with staining that was clearly weaker than that in the cancerous areas. EphB4 staining was observed in the basal layer cells of the squamous epithelium of the pharynx and esophagus and in the mucosal epithelial cells of the stomach, gallbladder, and large intestine. However, the staining was clearly weaker than in the cancerous areas. CLDN1 staining was observed in the acinar cells of the pancreas and skin, although it was weaker than in the cancerous area, and moderate staining was observed. LAT1 staining was observed in the cells of the basal layer of the squamous epithelium of the pharynx and esophagus, which was relatively strong. When performing treatments such as CAR-T cell therapy involving antibodies targeting ROBO1, EphB4, CLDN1, and LAT1, it is necessary to be careful of adverse events in normal organs where these antigens are expressed.




Figure 3. Expression of 5 common cancer-specific antigens in non-cancerous normal organs adjacent to various cancers. Representative examples of the expression patterns of 5 common cancer-specific antigens in non-cancerous normal organs (pharynx, mammary gland, esophagus, lung, stomach, liver, gallbladder, pancreas, colon, kidney, ovary, uterus, and skin) adjacent to the cancer lesions of a total of 385 cases of surgically resected advanced cancer are shown.

2.4. Development of a Companion Diagnostic Method for Simultaneously Determining the Expression of Common Cancer Membrane Protein Antigens and HLA Class I Using a Multiplexed Fluorescent Immunostaining System

Using a multiplexed fluorescent immunostaining system, we attempted to establish a companion diagnostic method for simultaneously determining the expression of five common cancer membrane protein antigens and HLA class I (Figure 4). In addition, using hepatocellular carcinoma PDXs and lung cancer cases 1 and 2 PDXs, we established a system for simultaneously staining five membrane protein common cancer antigens EphB4, ROBO1, LAT1, CLDN1, GPC3, and HLA class I in six colors (Figure 4A). Although GPC3 in hepatocellular carcinoma stains cytoplasm, we were able to establish a system for simultaneously staining six membrane proteins. Next, we evaluated the expression of these six antigens on the cell membrane using formalin-fixed paraffin sections of surgically resected specimens from actual cases of hepatocellular carcinoma, cholangiocarcinoma, and oropharyngeal carcinoma (Figure 4B).




Figure 4. Development of a companion diagnostic method for simultaneously determining the expression of common cancer-specific antigens and HLA class I using a multiplexed fluorescent immunostaining system. Using a multiplexed fluorescent immunostaining system, we attempted to establish a companion diagnostic method for simultaneously determining the expression of 5 common cancer-specific antigens and HLA class I. We established a system for simultaneously staining five membrane protein common cancer antigens EphB4, ROBO1, LAT1, CLDN1, GPC3, and HLA class I in six colors (A). We evaluated the expression of these six antigens on the cell membrane using formalin-fixed paraffin sections of surgically resected specimens from actual cases of hepatocellular carcinoma, cholangiocarcinoma, and oropharyngeal carcinoma (B).

2.5. A Scheme for Cocktail CAR-T Cell Therapy to Overcome the Diversity of Solid Tumors

If cocktail CAR-T cell therapy is developed that targets multiple of the five common membrane-expressed cancer antigens, it will likely be usable against most solid tumors (Figure 5).




Figure 5. A scheme for cocktail CAR-T cell therapy to overcome the diversity of solid tumors. If cocktail CAR-T cell therapy is developed that targets multiple of the five common membrane-expressed cancer antigens, it will likely be usable against most solid tumors.

3. Discussion

Genetically modified T cell therapy includes CAR-T cell therapy and TCR-T cell therapy. CAR-T can only target cell membrane protein antigens. Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane.

The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to “overcome the heterogeneity of cancer antigens.” For this purpose, it is necessary to target multiple cancer antigens simultaneously. In addition, to develop a CAR-T therapy that can be applied to many people, it is thought that the cancer antigens to be targeted are common cancer antigens expressed on the cell membrane in frequent cancers. We have selected five common membrane protein cancer antigens, including glypican-3 (GPC3), which have high cancer specificity and are frequently expressed in various cancers.

Most CAR-T therapies currently under development target only one antigen. It has become clear that even in patients who have achieved remission with CD19 CAR-T, recurrence of CD19-negative cancer may occur, and it has been said that it is necessary to target multiple antigens to increase efficacy. One of the five types of membrane protein common cancer antigens is expressed in most cancer tissues. This means that if a cocktail CAR-T therapy that combines multiple CARs against these antigens can be developed, it can be used as a treatment for most solid cancers. To create a new original CAR-T that targets these five types, we are conducting joint research with Optieum Biotechnologies Inc, which has a technology (Eumbody System™) to create a CAR-T cell library based on a single-chain antibody (scFv) library and screen CAR-T cells with optimal therapeutic effects from the library source. We have already identified some promising CARs that target these membrane protein common cancer antigens and plan to obtain promising CARs that target the remaining membrane protein common cancer antigens one after another in the future. In addition, the patient’s own T cells are usually collected by apheresis. CAR is introduced by a viral vector, which is time-consuming and costly to manufacture, making it inefficient. Recently, the risk of secondary T cell blood cancer in CAR introduction systems using retroviruses and lentiviruses has become apparent, shaking up the industry. In other words, the current manufacturing method has problems with time, cost, and safety. This is also true for allogeneic cells using iPS cells, and it cannot be said

that these problems have been eliminated even with CAR introduction systems using non-viral vectors.

We aim to develop a CAR-T cell therapy that prioritizes simplicity and safety while being effective. We aim to research and develop a system that does not use viral vectors but instead uses gene introduction of CAR in T cells with transient mRNA expression, allowing for repeated administration of smaller cells than usual. Safety is ensured by transient expression, and efficacy is ensured by repeated administration. In other words, by not using viral or non-viral vectors as a system for gene transfer of each CAR into T cells, the risk of secondary T-cell blood cancer, which is currently a problem, is eliminated. Furthermore, even if the target is a cancer-specific common cancer antigen, expression in normal tissues and cells is not completely absent, and by making the expression transient, safety is maximized. Furthermore, by preparing a repertoire of mRNA for many types of CARs off-the-shelf in advance, time and costs can be significantly reduced. Although there may be concerns about whether efficacy can be guaranteed because of the emphasis on safety and simplicity, this can be compensated for by being able to target many types of targets and by repeated administration.

CAR-T therapy, including CAR-T therapy targeting CD19, has shown remarkable effectiveness in blood cancers, but none has shown effectiveness in solid tumors, and there is worldwide competition. Many problems exist, such as high cost, complexity, and safety concerns. For CAR-T therapy targeting CD19, which has been proven effective, attempts are being made to create CAR-T by in vivo gene therapy [38]. Many studies have already been reported on creating CAR-T in the body using gene therapy vectors such as lentivirus (LV) vectors used in ex vivo CAR-T, adeno-associated virus (AAV) vectors, or by directly administering mRNA or DNA wrapped in nanocarriers such as LNPs, as used in the new coronavirus vaccine, and clinical applications are being planned at a speed far beyond our expectations. Although there are safety concerns, we are looking forward to the future. The five types of membrane protein common cancer antigens we selected could also be targets.

To overcome the heterogeneity of individual cancers and apply the antibody to a wide range of solid cancer patients, we collected five common cancer membrane protein antigens, such as GPC3. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1 [21–23], EphB4 [24–29], CLDN1 [30–33], and LAT1 [34–37] in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In addition, it was revealed that the cell membrane antigens EphB4, CLDN1, and LAT1 are frequently expressed in various solid cancers. CAR-T cell therapy targeting these antigens may be a savior for many solid cancer patients. In this study, we clarified the expression profiles of five common cancer membrane protein antigens collected to develop a cocktail of CAR-T cell therapies that can be applied to most solid tumor patients. Our CAR-T therapy targeting five common membrane protein cancer antigens, EphB4, CLDN1, LAT1, ROBO1, and GPC3, may be effective against many solid tumors, including childhood cancers. We will continue to develop cocktail CAR-T cell therapies that target these multiple common cancer membrane protein antigens.

4. Materials and Methods

4.1. Clinical Samples

The subjects of this study were Stage 2-4 head and neck cancer, breast cancer, esophageal cancer, lung cancer, gastric cancer, liver cancer, biliary tract cancer, pancreatic cancer, colorectal cancer, renal cell carcinoma, ovarian cancer, uterine cancer, various pediatric cancers (neuroblastoma, germ cell tumor, nephroblastoma: Wilms tumor, hepatoblastoma), and melanoma cases surgically resected at the National Cancer Center Hospital East, Kyoto Prefectural University of Medicine Hospital, Chiba University Hospital, and Kumamoto University Hospital from January 1, 2000 to August 31, 2024, as well as Stage 1 gastric cancer cases endoscopically resected at the National Cancer Center Hospital

East. Among these, cases in which thin-section specimens could be prepared from formalin-fixed paraffin-embedded blocks were the subjects of this study. The study was conducted with the approval of the research ethics committees of each institution (approval number 2020-352 from the National Cancer Center Research Ethics Committee). To facilitate comparison and analysis, we used specimens that contained cancerous and non-cancerous areas in the same block. Written informed consent was obtained from the patients, and the Declaration of Helsinki was used to conduct the study.

4.2. Immunohistochemical Analysis of Expression of Five Kinds of Common Cancer Membrane Protein Antigens

Immunohistochemical analysis was performed on 4 μm paraffin sections prepared from formalin-fixed paraffin blocks of human cancer tissues. Commercially available microarray slides of normal tissues were used (BioChain Institute.). Deparaffinization was performed using xylene and ethanol, and endogenous peroxidase was inactivated using 0.3% H_2O_2 /methanol. Antigen retrieval was performed using Target Retrieval Solution, pH 9 (Agilent Technologies) or heat treatment in a pressure cooker or microwave in AR6 (Akoya Biosciences) inactivation buffer. After blocking with porcine serum, primary antibodies against each antigen were reacted. Glypican-3 (BIOMOSICS®GPC3, 300-fold dilution), roundabout guidance receptor 1 (Proteintech® ROBO1, 300-fold dilution), Ephrin type-B receptor 4 (Cell Signaling Technology® EphB4, 300-fold dilution), Claudin 1 (Cell Signaling Technology® CLDN1, 300-fold dilution), L-type amino acid transporter 1 (abcam® LAT1, 200-fold dilution). The secondary antibody was used as polymer reagent (EnVision+ System- HRP Labelled Polymer Anti-Rabbit or EnVision+ System- HRP Labelled Polymer Anti-Mouse). Liquid DAB+ Substrate Chromogen System was used for color development. After counterstaining with hematoxylin, the specimens were dehydrated and cleared using ethanol and xylene, and the specimens were made into virtual slides using a NanoZoomer (Hamamatsu Photonics). The intracellular localization of tumor tissue was also evaluated by immunohistochemical analysis. The presence and localization (whether cell membrane or not) of staining were evaluated in tumor cells for each case. Three researchers analyzed immunohistochemical staining with these methods.

4.3. Multiplex Fluorescence Immunohistochemical Staining and Analysis of Cancer Antigens and HLA Class I

Multiplex fluorescent immunohistochemistry (MFIH) was performed on 4 μm -thick tissue sections of various cancers using the PerkinElmer Opal kit. Fluorescent multiplex histochemistry images were acquired using a tissue section quantitative analysis imaging system (Vectra 3), and up to 20 regions of interest (ROIs) ($699 \times 500 \mu\text{m}$) were randomly selected in the center and margin of each tumor and evaluated using an image analysis program (Inform 2.6., PerkinElmer, Inc.). The distribution of specific cancer antigens was also analyzed. HLA class I and five common cancer membrane protein antigens (CLDN1, EphB4, LAT1, ROBO1, and GPC3) were selected as objects for MFIH.

Author Contributions: Tetsuya Nakatsura: Conceptualization, Formal analysis, Funding acquisition, Investigation, Project administration, Supervision, Validation, Roles/Writing—original draft, original draft/Roles/Writing—original draft. Kazumasa Takenouchi: Data curation, Formal analysis, Investigation; Project administration, Resources; Validation. Jun Kataoka: Data curation, Formal analysis, Investigation, Resources, Validation. Yusuke Ito: Data curation, Formal analysis; Investigation, Resources. Sae Kikuchi: Data curation. Hiroki Kinoshita: Formal analysis, Investigation, Validation. Kazunobu Ohnuki; Data curation, Investigation, Validation. Toshihiro Suzuki: Investigation, Validation. Nobuo Tsukamoto: Investigation, Validation.

Funding: This work was supported in part by the National Cancer Center Research and Development Fund (2022-A-9), JST START Project Promotion Type (Commercialization Support), Grant Number JPMJST2211, and AMED under Grant Number JP23fk0210093, JP24fk0210152, JP24ck0106919, and JP24bm1123042.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the National Cancer Center Research Ethics Committee (protocol code 2020-352 and date of approval).

Informed Consent Statement: Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: We thank Naoki Yagi, Masatake Taniguchi, and the Division of Cancer Immunotherapy, EPOC, National Cancer Center members for technical and experimental support. We also thank the many doctors: Dr. Natsuura, Dr. Ohnishi, Dr. Tsuboi, Dr. Fujita, Dr. Kinoshita, Dr. Ito, Dr. Gotohda, Dr. Masuda, Dr. Yajima, Dr. Tabe, Dr. Yano, Dr. Ishii, Dr. Watanabe, Dr. Sakashita in the National Cancer Center Hospital East, Dr. Yagyu in the Kyoto Prefectural University of Medicine Hospital, Dr. Hishiki, in the Chiba University Hospital, and Dr. Fukushima in the Kumamoto University Hospital for the case and specimen selection and provision.

Conflicts of Interest: Author Tetsuya Nakatsura (TN) has received research grants from BrightPath Biotherapeutics Co., Ltd., Thyas Co., Ltd., ONOPHARMACEUTICAL CO., Ltd., Resonac Corporation, MEDINET Co., Ltd., NapaJen Pharma Inc, Heartseed Inc, Takara BIO Inc, DAICEL CORPORATION, NA Vaccine Institute CO., Ltd., Logomix Inc, Optieum Biotechnologies Inc, and MaxCyte, Inc. TN hold Stock Ownership, Stock Option or Profits from Noile-Immune Biotech Inc., Logomix Inc, and Optieum Biotechnologies Inc. TN have royalties from OncoTherapyScience, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

CAR	chimeric antigen receptor
GPC3	glypican-3
ROBO1	roundabout guidance receptor 1
EphB4	Eph receptor B4
CLDN1	claudin-1
LAT1	L-type amino acid transporter 1

References

1. A. Couzinet, T. Suzuki, T. Nakatsura, Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy, *Expert Opin Ther Targets*. 28 (10) (2024) 895-909.
2. J. Charneau, T. Suzuki, M. Shimomura, N. Fujinami, T. Nakatsura. Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. *J Hepatocell Carcinoma*. 8 (2021) 1035-1054.
3. M. Taniguchi, S. Mizuno, T. Yoshikawa, N. Fujinami, M. Sugimoto, S. Kobayashi, S. Takahashi, M. Konishi, N. Gotohda, T. Nakatsura. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. *Cancer Sci*. 111 (8) (2020) 2747-2759.
4. Y. Shimizu, T. Suzuki, T. Yoshikawa, I. Endo, T. Nakatsura. Next-Generation Cancer Immunotherapy Targeting Glypican-3. *Front Oncol*. 9 (2019) 248.
5. N. Tsuchiya, A. Hosono, T. Yoshikawa, K. Shoda, K. Nosaka, M. Shimomura, J. Hara, C. Nitani, A. Manabe, H. Yoshihara, Y. Hosoya, H. Kaneda, Y. Kinoshita, K. Kohashi, K. Yoshimura, N. Fujinami, K. Saito, S.

- Mizuno, T. Nakatsura. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. *Oncoimmunology*. 7 (2017) e1377872.
6. Y. Shimizu, T. Suzuki, T. Yoshikawa, N. Tsuchiya, Y. Sawada, I. Endo, T. Nakatsura. Cancer immunotherapy-targeted glypican-3 or neoantigens. *Cancer Sci*, 109 (2018) 531-541.
 7. N. Tsuchiya, T. Yoshikawa, N. Fujinami, K. Saito, S. Mizuno, Y. Sawada, I. Endo, T. Nakatsura. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. *Oncoimmunology*. 6 (2017) e1346764.
 8. S. Suzuki, J. Sakata, F. Utsumi, R. Sekiya, H. Kajiyama, K. Shibata, F. Kikkawa, T. Nakatsura. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. *Oncoimmunology*. 5 (2016) e1238542.
 9. Y Sawada, T Yoshikawa, K Ofuji, M Yoshimura, N Tsuchiya, M. Takahashi, D. Nobuoka, N. Gotohda, S. Takahashi, Y. Kato, M. Konishi, T. Kinoshita, M. Ikeda, K. Nakachi, N. Yamazaki, S. Mizuno, T. Takayama, K. Yamao, K. Uesaka, J. Furuse, I. Endo, T. Nakatsura. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. *Oncoimmunology*. 5 (2016) e1129483.
 10. S. Suzuki, K. Shibata, F. Kikkawa, T. Nakatsura. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. *Hum Vaccin Immunother*. 10 (2014) 338-343.
 11. Y. Tada, T. Yoshikawa, M. Shimomura, Y. Sawada, M. Sakai, H. Shirakawa, D. Nobuoka, T. Nakatsura. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide. *Int J Oncol*. 43 (2013) 1019-1026.
 12. Y. Sawada, T. Yoshikawa, S. Fujii, S. Mitsunaga, D. Nobuoka, S. Mizuno, M. Takahashi, C. Yamauchi, I. Endo, T. Nakatsura. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. *Hum Vaccin Immunother*. 6 (2013) 228-233.
 13. Y. Sawada, T. Yoshikawa, D. Nobuoka, H. Shirakawa, T. Kuronuma, Y. Motomura, S. Mizuno, H. Ishii, K. Nakachi, M. Konishi, T. Nakagohri, S. Takahashi, N. Gotohda, T. Takayama, K. Yamao, K. Uesaka, J. Furuse, T. Kinoshita, T. Nakatsura. Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. *Clin Cancer Res*. 18 (2012) 3686-3696.
 14. T. Yoshikawa, M. Nakatsugawa, S. Suzuki, H. Shirakawa, D. Nobuoka, N. Sakemura, Y. Motomura, Y. Tanaka, S. Hayashi, T. Nakatsura. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. *Cancer Sci*. 102 (2011) 918-925.
 15. H. Shirakawa, H. Suzuki, M. Shimomura, M. Kojima, N. Gotohda, S. Takahashi, T. Nakagohri, M. Konishi, N. Kobayashi, T. Kinoshita, T. Nakatsura. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. *Cancer Sci*. 100 (2009) 1403-1407.
 16. Y. Motomura, Y. Ikuta, T. Kuronuma, H. Komori, M. Ito, M. Tsuchihara, Y. Tsunoda, H. Shirakawa, H. Baba, Y. Nishimura, T. Kinoshita, T. Nakatsura. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. *Int J Oncol*. 32 (2008) 985-990.
 17. H. Komori, T. Nakatsura, S. Senju, Y. Yoshitake, Y. Motomura, Y. Ikuta, D. Fukuma, K. Yokomine, M. Harao, T. Beppu, M. Matsui, T. Torigoe, N. Sato, H. Baba, Y. Nishimura. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. *Clin Cancer Res*. 12 (2006) 2689-2697.
 18. T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, Y. Nishimura. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. *Clin Cancer Res*. 10 (2004) 8630-8640.
 19. Akazawa, D. Nobuoka, M. Takahashi, T. Yoshikawa, M. Shimomura, S. Mizuno, T. Fujiwara, Y. Nakamoto, T. Nakatsura. Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. *Cancer Sci*. 110 (2019) 1842-1852.
 20. D. Nobuoka, T. Yoshikawa, M. Takahashi, T. Iwama, K. Horie, M. Shimomura, S. Suzuki, N. Sakemura, M. Nakatsugawa, H. Sadamori, T. Yagi, T. Fujiwara, T. Nakatsura. Intratumoral peptide injection enhances

- tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. *Cancer Immunol Immunother.* 62 (2013) 639-652.
21. H. Ito, S. Funahashi, N. Yamauchi, J. Shibahara, Y. Midorikawa, S. Kawai, Y. Kinoshita, A. Watanabe, Y. Hippo, T. Ohtomo, H. Iwanari, A. Nakajima, M. Makuuchi, M. Fukayama, Y. Hirata, T. Hamakubo, T. Kodama, M. Tsuchiya, H. Aburatani. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. *Clin Cancer Res.* 12 (2006) 3257.
 22. Z. Zhao, J. Li, Y. Jiang, W. Xu, X. Li, W. Jing. CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. *Med. Sci. Monit.* 23 (2017) 2906-2916.
 23. H. Tong, T. Li, W. Qiu, Z. Zhu. Claudin-1 silencing increases sensitivity of liver cancer HepG2 cells to 5-fluorouracil by inhibiting autophagy. *Oncol. Lett.* 18 (2019) 5709-5716.
 24. R. Kumar, J. Singh, G. Xia, V. Krasnoperov, L. Hassanieh, E. J. Ley, J. Scheinet, N. G. Kumar, D. Hawes, M. F. Press, F. A. Weaver, P. S. Gill. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. *Am J Pathol.* 169 (2006) 279-293.
 25. R. Masood, S. R. Kumar, U. K. Sinha, D. L. Crowe, V. Krasnoperov, R. K. Reddy, S. Zozulya, J. Singh, G. Xia, D. Broek, A. H. Schonthal, P. S. Gill. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. *Int J Cancer.* 119 (2006) 1236-1248.
 26. S. R. Kumar, J. S. Scheinet, E. J. Ley, J. Singh, V. Krasnoperov, R. Liu, P. K. Manchanda, R. D. Ladner, D. Hawes, F. A. Weaver, R. W. Beart, G. Singh, C. Nguyen, M. Kahn, P. S. Gill. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. *Cancer Res.* 69 (2009) 3736-3745.
 27. H. Kubo, S. Yagyu, K. Nakamura, K. Yamashima, A. Tomida, K. Kikuchi, T. Iehara, Y. Nakazawa, H. Hosoi. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. *Mol Ther Oncolytics.* 20 (2021) 646-658.
 28. S. Yagyu, H. Mochizuki, K. Yamashima, H. Kubo, S. Saito, M. Tanaka, K. Sakamoto, A. Shimoi, Y. Nakazawa. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. *Clin Transl Immunology.* 10 (2021) e1291.
 29. S. Liu, D. Li, R. Park, R. Liu, Z. Xia, J. Guo, V. Krasnoperov, P. S. Gill, Z. Li, H. Shan, P. S. Conti. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with ⁶⁴Cu-labeled hAb47 and hAb131 antibodies. *J Nucl Med.* 54 (2013) 1094-1100.
 30. Z.R. Visco, G. Sfakianos, C. Grenier, M.-H. Boudreau, S. Simpson, I. Rodriguez, R. Whitaker, D.Y. Yao, A. Berchuck, S.K. Murphy, Z. Huang. Epigenetic regulation of claudin-1 in the development of ovarian cancer recurrence and drug resistance. *Front. Oncol.* 11 (2021) 620873.
 31. Z. Zhao, J. Li, Y. Jiang, W. Xu, X. Li, W. Jing. CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. *Med. Sci. Monit.* 23 (2017) 2906-2916.
 32. P. Dhawan, A.B. Singh, N.G. Deane, Y. No, S.R. Shiou, C. Schmidt, J. Neff, M.K. Washington, R.D. Beauchamp. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. *J. Clin. Invest.* 115 (2005) 1765-1776.
 33. N. Oku, E. Sasabe, E. Ueta, T. Yamamoto, T. Osaki. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. *Cancer Res.* 66(2006) 5251-5257.
 34. Q. Wang, J. Holst. L-Type amino acid transporter and cancer: targeting the mTORC1 pathway to inhibit neoplasia. *Am. J. Cancer Res.* 5 (2015) 1281-1294.
 35. Y. Ohno, K. Suda, K. Masuko, H. Yagi, Y. Hashimoto, T. Masuko. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino acid transporter 1. *Cancer Sci.* 99 (2008) 1000-1007.
 36. S. Nozaki, Y. Nakatani, A. Mawatari, W. E. Hume, Y. Wada, A. Ishii, M. Tanaka, N. Tsuyuguchi, H. Doi, Y. Watanabe. First-in-human assessment of the novel LAT1 targeting PET probe 18F-FIMP. *Biochem Biophys Res Commun.* 596 (2022) 83-87.

37. Y. Kanai. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. *Pharmacol Ther.* 230 (2022) 107964.
38. E Pinto, L Lione, M Compagnone, M Paccagnella, E Salvatori, M Greco, V Frezza, E Marra, L Aurisicchio, G Roscilli, A Conforti. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. *J Transl Med.* 23 (2025) 10.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.